Pathfinder Cell Therapy, Inc.
PFND · OTC
12/31/2014 | 12/31/2013 | 12/31/2012 | 12/31/2011 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.04 | 0.25 | 0.07 | -0.00 |
| FCF Yield | -180.43% | -17.14% | -15.17% | -8.86% |
| EV / EBITDA | -4.92 | -8.37 | -7.30 | -7.34 |
| Quality | ||||
| ROIC | 116.56% | 302.21% | 202.04% | -4,019.29% |
| Gross Margin | 0.00% | 31.48% | 56.14% | 64.38% |
| Cash Conversion Ratio | 0.69 | 0.94 | 0.94 | 0.21 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -9.56% | -30.80% | -41.25% |
| Free Cash Flow Growth | 39.85% | 20.90% | 13.13% | -80.62% |
| Safety | ||||
| Net Debt / EBITDA | -4.44 | -2.48 | -0.76 | -0.03 |
| Interest Coverage | 0.00 | 0.00 | -21.46 | 36.35 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 1.52 | 0.51 |
| Cash Conversion Cycle | 0.00 | -1,874.32 | -224.25 | -2,425.38 |